02:33 PM EDT, 09/29/2025 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Monday it expects to resubmit its biologics license application for ONS-5010, an investigational treatment for wet macular degeneration, after completing a Type A meeting with the US Food and Drug Administration.

After reviewing the agency's feedback and meeting minutes, the company said it expects to resubmit the application before the end of the year.

The company's shares were up more than 10% in recent trading on Monday.

Price: 1.06, Change: +0.08, Percent Change: +8.75